Functional Study of a Camelid Single Domain Anti-CD22 Antibody

被引：2

作者：

Faraji, Fatemeh ^{[1
,2
]}

Habibi-Anbouhi, Mahdi ^{[3
]}

Behdani, Mahdi ^{[4
]}

Kazemi-Lomedasht, Fatemeh ^{[4
]}

Shokrgozar, Mohammad Ali ^{[3
]}

Zarnani, Amir-Hassan ^{[5
]}

Tajik, Nader ^{[1
]}

机构：

[1] Iran Univ Med Sci, Immunol Res Ctr IRC, Tehran, Iran

[2] Iran Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran

[3] Pasteur Inst Iran, Natl Cell Bank Iran, Tehran, Iran

[4] Pasteur Inst Iran, Biotechnol Res Ctr, Venom & Biotherapeut Mol Lab, Tehran, Iran

[5] Univ Tehran Med Sci, Sch Publ Hlth, Dept Immunol, Tehran, Iran

来源：

INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS | 2020年 / 26卷 / 02期

关键词：

Anti-CD22; VHH; Cell proliferation; Apoptosis; B-CELL ANTIGEN; MONOCLONAL-ANTIBODY; TARGETING CD22; EPRATUZUMAB; NANOBODY; INTERNALIZATION; IDENTIFICATION; ACTIVATION; APOPTOSIS; FRAGMENT;

D O I：

10.1007/s10989-019-09870-y

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Variable antigen-binding domain of camelid single chain antibodies (VHH, Nanobody) and its conjugates are considered among very promising candidates in tumor diagnosis and treatment because of its small size, stability, and favorable bio-distribution. CD22 is a receptor that is expressed on most B cells and modulates their function. Targeting CD22 in B cell malignancies and disorders by monoclonal antibodies has shown promising results in vitro and in clinical trials. In this study, we investigate the impact of an anti-human CD22 VHH binding to CD22 on B cells and its internalization following attachment. Our findings demonstrate the proliferation inhibiting of these cells with no effect on apoptosis, in addition to the rapid internalization of the VHH.

引用

页码：633 / 639

页数：7

共 50 条

[41] Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma
Li, Su
Zhang, Dongsheng
Sun, Jian
Li, Zhinming
Deng, Liting
Zou, Benyan
Zhan, Jing
Jiang, Wenqi
MABS, 2012, 4 (02) : 256 - 266
[42] Structure and Properties of a Complex of α-Synuclein and a Single-Domain Camelid Antibody
De Genst, Erwin J.
Guilliams, Tim
Wellens, Joke
O'Day, Elizabeth M.
Waudby, Christopher A.
Meehan, Sarah
Dumoulin, Mireille
Hsu, Shang-Te Danny
Cremades, Nunilo
Verschueren, Koen H. G.
Pardon, Els
Wyns, Lode
Steyaert, Jan
Christodoulou, John
Dobson, Christopher M.
JOURNAL OF MOLECULAR BIOLOGY, 2010, 402 (02) : 326 - 343
[43] Amplified induction of apoptosis in Burkitt Lymphoma cells by anti-FAS monoclonal antibody in combination with anti-CD22 immunotoxin.
de Totero, D
Tazzari, PL
Bolognesi, A
Polito, L
Cutrona, G
Stirpe, F
Gobbi, M
EXPERIMENTAL HEMATOLOGY, 1999, 27 (07) : 47 - 47
[44] Purification and functional characterization of a Camelid-like single-domain antimycotic antibody by engineering in affinity tag
Kabir, M. Enamul
Krishnaswamy, Senthilkumar
Miyamoto, Masahiko
Furuichi, Yasuhiro
Komiyama, Tadazumi
PROTEIN EXPRESSION AND PURIFICATION, 2010, 72 (01) : 59 - 65
[45] THE ANTITUMOR-ACTIVITY OF AN ANTI-CD22 IMMUNOTOXIN IN SCID MICE WITH DISSEMINATED DAUDI LYMPHOMA IS ENHANCED BY EITHER AN ANTI-CD19 ANTIBODY OR AN ANTI-CD19 IMMUNOTOXIN
GHETIE, MA
TUCKER, K
RICHARDSON, J
UHR, JW
VITETTA, ES
BLOOD, 1992, 80 (09) : 2315 - 2320
[46] Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study
Serge D Steinfeld
Laure Tant
Gerd R Burmester
Nick KW Teoh
William A Wegener
David M Goldenberg
Olivier Pradier
Arthritis Research & Therapy, 8
[47] Multivalent anti-CD20/anti-CD22 bispecific antibody fusion proteins made by the DNL method show potent lymphoma cytotoxicity.
Rossi, Edmund A.
Losman, Michele J.
Nordstrom, Diane L.
Cardillo, Thomas
Loo, Meiyu
Kopinski, John
Qu, Zhengxing
Goldenberg, David M.
Chang, Chien-Hsing
BLOOD, 2006, 108 (11) : 707A - 707A
[48] Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
Dreyzin, Alexandra
Panch, Sandhya R.
Shalabi, Haneen
Yates, Bonnie
Highfill, Steven L.
Jin, Ping
Stroncek, David
Shah, Nirali N.
MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 28 : 51 - 61
[49] CHIMERIC LL2 (CLL2) ANTI-CD22
LEUNG, SO
HYBRIDOMA, 1994, 13 (06): : 549 - 549
[50] Sodium orthovanadate (NaV) effects CD22 expression, intracellular signaling, and lymphomacidal activity of the HB22.7 anti-CD22 monoclonal antibody.
O'Donnell, RT
Pearson, D
McKnight, H
Tedder, TF
Tuscano, JM
BLOOD, 2005, 106 (11) : 428A - 428A

← 1 2 3 4 5 →